Modified Islet Transplants Show Promise for Insulin Independence in Type 1 Diabetes

Type 1 diabetes develops when the immune system attacks and destroys the insulin-producing beta cells in the pancreas. One promising treatment approach involves transplanting healthy islet cells—the clusters of cells in the pancreas that produce insulin—to replace the damaged ones.

However, transplanted islets face a major hurdle: the recipient's immune system recognizes them as foreign and tries to reject them. Current transplant protocols typically require patients to take immunosuppressive medications that weaken the entire immune system to prevent rejection. While effective at protecting the transplant, these drugs carry significant side effects and increase vulnerability to infections and other complications.

Researchers at the University of Missouri School of Medicine took a different approach. Instead of suppressing the entire immune system, they engineered the islet cells themselves by adding two immune-regulating molecules that act as a protective shield.

"We provided islets with a protective shield consisting of two molecules that help the transplants evade rejection from the immune system, a solution that lengthens the survival of islet cells with minimal side effects," explained study author Haval Shirwan. This targeted strategy focuses protection directly on the transplanted cells rather than dampening overall immune function.

In preclinical models, the engineered islets demonstrated encouraging outcomes. Over 72% of recipients who received the modified transplants achieved normal blood glucose levels without requiring insulin medication. The two protective molecules allowed the transplanted cells to function normally—responding to blood sugar changes and secreting insulin as needed—while remaining protected from immune attack.

This research represents an important step toward making islet transplantation a more practical option for people with Type 1 diabetes. By reducing or eliminating the need for immunosuppressive medications, engineered islets could offer better long-term outcomes with fewer complications.

It's important to note that this is early-stage research conducted in preclinical models. Significant development and human clinical trials would be needed before this approach becomes available as a treatment. Researchers continue to refine the technology and test its safety and effectiveness in living systems.

Origin: Biopharma from Technology Networks (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.